Takeda to Pay Amylin Up to $1 Billion to Develop Obesity Drugs

Nov. 2 (Bloomberg) -- Takeda Pharmaceutical Co., maker of the world’s best-selling diabetes drug, agreed to pay as much as $1 billion, including $75 million upfront, to Amylin Pharmaceuticals Inc. to co-develop obesity treatments. The deal includes...